Table 3 Baseline characteristics of HCV infection of patients included in the ANRS CO 13 HEPAVIH cohort of HIV-HCV co-infected patients, France, 2006-2008
Total N=1175 | HCV chronically infected patients N=1048 | Sustained HCV responders N=127 | |
|---|---|---|---|
Years since HCV diagnosis, median (IQR) | - | 10 (6-14) | - |
HCV genotype, N (%) | - | - | |
1 | 577 (56.0) | ||
2 | 39 (3.8) | ||
3 | 187 (18.1) | ||
4 | 225 (21.8) | ||
5 or other | 3 (0.3) | ||
HCV plasma RNA (Log10) (IU/ML), median (IQR) | - | 6.2 (5.7-6.5) | - |
Past anti HCV therapy, N (%) | |||
Interferon alone | 40 (3.4) | 33 (3.1) | 7 (5.5) |
Interferon+ ribavirin | 93 (7.9) | 65 (6.2) | 28 (22) |
Pegylated interferon plus ribavirin | 365 (31.1) | 273 (26.0) | 92 (72.5) |
Cirrhosis*, N (%) | 255 (25.2) | 229 (25.0) | 26 (26.8) |
Documented decompensated liver disease, N (%) | 32 (2.7) | 27 (2.6) | 5 (3.9) |